Reviva Pharmaceuticals Holdings, Inc. (RVPH) Stock Forecast
RVPH analyst forecast
as of October 21, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 6 analysts
- Price target
- $17.50 average of analyst targets
- Upside to target
- +3,840.6% from the latest close
- Next earnings
- —
- 52-week range
- $0.33 – $14.60
RVPH analyst ratings
6 analystsNumber of analysts at each rating.
RVPH price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RVPH earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.18 | −$0.18 | −$0.18 | −$1.20 | +85.0% | 1 |
| Current fiscal year (2026) | −$0.85 | −$0.85 | −$0.85 | −$5.48 | +84.5% | 1 |
| Next fiscal year (2027) | −$0.85 | −$0.85 | −$0.85 | −$0.85 | 0.0% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RVPH revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 1 |
RVPH EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RVPH EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.23 | −$0.36 | −$0.36 | −$0.36 | −$0.18 | −21.7% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.95 | −$1.60 | −$1.60 | −$1.60 | −$0.85 | −10.5% | 1 up · 0 down |
| Next fiscal year (2027) | −$1.02 | −$1.90 | −$1.90 | −$1.90 | −$0.85 | −17.1% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RVPH earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; RVPH beat in 7 of 12.
What analysts expect from RVPH
6 analysts cover Reviva Pharmaceuticals; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $17.50, 3,840.6% above the latest close of $0.44. Analysts expect earnings of −$0.85 per share for 2026, +84.5% from a year earlier. For 2027 the average estimate is −$0.85 per share. Reviva Pharmaceuticals beat the EPS estimate in 7 of the last 12 quarters.
Related: RVPH income statement, RVPH key metrics, RVPH chart. See the RVPH stock overview for the latest quote and news.
RVPH forecast FAQ
What is Reviva Pharmaceuticals's price target?
The average analyst price target for Reviva Pharmaceuticals is $17.50, 3,840.6% above the latest close of $0.44.
Is Reviva Pharmaceuticals a buy, hold or sell?
Of 6 analysts covering Reviva Pharmaceuticals, 3 rate it a strong buy, 3 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Reviva Pharmaceuticals's EPS forecast?
Analysts forecast −$0.85 per share for 2026 (range −$0.85 to −$0.85); for 2027 the estimate is −$0.85.
Does Reviva Pharmaceuticals usually beat earnings estimates?
Reviva Pharmaceuticals reported EPS at or above the analyst estimate in 7 of the last 12 quarters.